GCM
RLMD icon

Graham Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Graham Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$93.9K Sell
13,493
-12,115
-47% -$57.3K ﹤0.01% 1051
2025
Q4 		$124K Buy
+25,608
New +$85.8K ﹤0.01% 1125
2023
Q1 		– Sell
-26,258
Closed -$91.6K – 1290
2022
Q4 		$91.6K Buy
+26,258
New +$231K ﹤0.01% 999

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Graham Capital Management's RLMD Position: Q1 2026 in Review

Graham Capital Management reduced its Relmada Therapeutics (RLMD) stake by 47% in Q1 2026, selling an estimated $57.3K and leaving 13,493 shares worth $93.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1051.

Graham Capital Management first reported a position in RLMD in Q4 2022 and has held it in 3 quarters since. The position peaked at $124K in Q4 2025. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Graham Capital Management held 13,493 shares of Relmada Therapeutics worth $93.9K as of Q1 2026.
  • Graham Capital Management sold 12,115 Relmada Therapeutics shares in Q1 2026, an estimated $57.3K.
  • Relmada Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q1 2026, its #1051 holding.
  • Graham Capital Management first reported a position in Relmada Therapeutics in Q4 2022 and has held it in 3 quarters since.
  • Graham Capital Management's Relmada Therapeutics position peaked at $124K in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.